Academisch Ziekenhuis Leiden (h.o.d.n. Lumc)

Leiden University Medical Center

Inova Diagnostics, Inc.

Other

Leendert Adrianus Trouw

Reinaldus Everardus Maria Toes

Thomas Willem Johannes Huizinga

Jing Shi

Anthony Cerami

Petrus Antonius Van Veelen

Jan Wouter Drijfhout

Michael Mahler

René Toes

Peter Van Veelen

Tom Huizinga

Thomas Willem Huizinga

Hans Ulrich Scherer

Reinaldus Everadus Maria Toes

Reinaldus Everardus Toes

Means and methods for determining whether an individual that does not have rheumatoid arthritis, AAV or Sjögren syndrome at the moment of sampling is at risk of developing the disease, the method comprising determining whether an antibody-containing sample of the individual comprises an autoantibody associated with the disease that comprises an N-linked glycosylation at one or more positions in a Fab-portion of the antibody, the method further comprising determining the risk of the individual for developing the disease. The disease is preferably rheumatoid arthritis.

Fab-linked glycans as biomarker for the transition from a pre-disease 'at-risk-phase' to rheumatoid arthritis; AAV or Sjögren syndrome

The present disclosure relates to the field of molecular biology and more specifically to methods for detecting anti-carbamylated protein (anti-CarP) antibodies in the serum of rheumatoid arthritis (RA) patients.

Compositions and methods for the diagnosis of rheumatoid arthritis

Antibodies against citrullinated protein antigens (ACPA) have shown their relevance for the diagnosis and possibly pathogenesis in arthritis. Described are means and methods for determining antibodies against homocitrulline-containing proteins or carbamylated proteins/peptides (anti-CarP) for the classification of individuals suffering from, or at risk of suffering from, arthritis.

Anti-carbamylated protein antibodies and the risk for arthritis

Growing community of inventors

Leiden, Netherlands

Leendert Adrianus Trouw